Do you want to read an article? Please log in or register.
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone
Pulmonary Fibrosis
RECOMMENDED
Related content
Lung Cancer
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study
Br J Clin Pharmacol
Grande E, Giovannini M, Marriere E, Pultar P, Quinlan M, Chen X, Rahmanzadeh G, Curigliano G, Cui X
doi: 10.1111/bcp.14697
RECOMMENDED
Pulmonary Fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS
doi: 10.1186/s12931-020-01458-1.
RECOMMENDED
Pulmonary Fibrosis
Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH
doi: 10.1513/AnnalsATS.202007-901OC
RECOMMENDED
Tuberculosis
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis
Am J Respir Crit Care Med.
Dheda K, Lenders L, Magombedze G, Srivastava S, Raj P, Arning E, Ashcraft P, Bottiglieri T, Wainwright H, Pennel T, Linegar A, Moodley L, Pooran A, Pasipanodya JG, Sirgel FA, van Helden PD, Wakeland E, Warren RM, Gumbo T
doi: 10.1164/rccm.
Pulmonary Fibrosis
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Expert Opin Emerg Drugs.
Aryal S, Nathan SD
doi: 10.1080/14728214.
RECOMMENDED
Pulmonary Fibrosis
Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med.
Vianello A, Salton F, Molena B, Turato C, Graziani ML, Braccioni F, Frassani V, Sella D, Pretto P, Paladini L, Sukthi A, Confalonieri M
doi: 10.3390/jcm9020422.
RECOMMENDED
Pulmonary Fibrosis
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Belhassen M, Dalon F, Nolin M, Van Ganse E
doi: 10.1186/s12931-021-01714-y
RECOMMENDED
Pulmonary Fibrosis
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med.
Cerri S, Monari M, Guerrieri A, Donatelli P, Bassi I, Garuti M, Luppi F, Betti S, Bandelli G, Carpano M, Bacchi Reggiani ML, Tonelli R, Clini E, Nava S
doi: 10.1016/j.rmed.2019.105803.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.